Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JASWINDER SINGH

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1093747677
CMS profile
185961
Location
KANSAS CITY, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$3,066.80

163 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,997.80 162
Education $69.00 1

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 163 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JASWINDER SINGH

NPI 1093747677 · CMS profile ID 185961

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

KANSAS CITY, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 163 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1093747677?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JASWINDER SINGH, NPI 1093747677, CMS profile ID 185961. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 163 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1093747677?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). JASWINDER SINGH, NPI 1093747677, CMS profile ID 185961. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 163 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1093747677?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
JASWINDER SINGH, NPI 1093747677, CMS profile ID 185961, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 163 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1093747677?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

163 matching records · $3,066.80 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 163 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 163.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Eisai Inc. $25.9609/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110751328 CMS
Exelixis Inc. $16.6309/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138559136 CMS
GlaxoSmithKline, LLC. $21.2009/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116241455 CMS
PFIZER INC. $2.2409/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132024103 CMS
PFIZER INC. $8.0609/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131347191 CMS
Astellas Pharma US Inc $16.4409/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139400131 CMS
Merck Sharp & Dohme LLC $21.9909/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141580341 CMS
E.R. Squibb & Sons, L.L.C. $13.5009/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101415051 CMS
Novartis Pharmaceuticals Corporation $19.7209/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087270191 CMS
Novartis Pharmaceuticals Corporation $14.7509/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087270193 CMS
ABBVIE INC. $23.2508/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106110318 CMS
Gilead Sciences, Inc. $14.9008/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133801300 CMS
AstraZeneca Pharmaceuticals LP $15.3008/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105677999 CMS
Merck Sharp & Dohme LLC $16.1108/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141831190 CMS
Daiichi Sankyo Inc. $16.8808/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089483851 CMS
Celgene Corporation $15.3008/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101132200 CMS
Gilead Sciences, Inc. $10.6108/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133801298 CMS
ARRAY BIOPHARMA INC $2.1008/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131356001 CMS
ARRAY BIOPHARMA INC $23.1408/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131358191 CMS
PFIZER INC. $1.0708/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131901837 CMS
PUMA BIOTECHNOLOGY, INC. $22.3408/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1113856976 CMS
Takeda Pharmaceuticals U.S.A., Inc. $19.2408/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144967839 CMS
Merck Sharp & Dohme LLC $25.8208/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141831174 CMS
PFIZER INC. $14.7008/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131345344 CMS
Ipsen Biopharmaceuticals, Inc $16.6608/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091960560 CMS
AstraZeneca Pharmaceuticals LP $20.9408/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105889799 CMS
Novartis Pharmaceuticals Corporation $24.4708/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087270183 CMS
Novartis Pharmaceuticals Corporation $0.6108/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087270185 CMS
ABBVIE INC. $27.9507/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106110316 CMS
GlaxoSmithKline, LLC. $22.4507/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116324588 CMS
Merck Sharp & Dohme LLC $17.5207/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141831172 CMS
PFIZER INC. $15.3007/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131346465 CMS
PFIZER INC. $11.8807/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131811870 CMS
PFIZER INC. $5.0007/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131813348 CMS
Regeneron Healthcare Solutions, Inc. $29.9107/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114175876 CMS
ABBVIE INC. $8.3407/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106110314 CMS
GlaxoSmithKline, LLC. $27.7207/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116663487 CMS
Merck Sharp & Dohme LLC $17.1307/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141580343 CMS
Novartis Pharmaceuticals Corporation $13.1907/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087270181 CMS
PFIZER INC. $3.4707/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131811872 CMS
Gilead Sciences, Inc. $17.0307/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133801296 CMS
GlaxoSmithKline, LLC. $19.7007/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116537284 CMS
SOBI, INC $21.2507/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141425573 CMS
Celgene Corporation $16.4106/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101132194 CMS
ABBVIE INC. $30.2106/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106110312 CMS
Gilead Sciences, Inc. $12.4106/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133801294 CMS
PFIZER INC. $5.3406/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131699283 CMS
PFIZER INC. $7.0806/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131813350 CMS
GENZYME CORPORATION $18.3206/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139750805 CMS
JAZZ PHARMACEUTICALS INC. $23.5606/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150198979 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $17,723.02 146
PY2020 $7,018.23 51
PY2021 $2,569.81 107
PY2022 $3,167.49 168
PY2023 $5,473.31 157
PY2024 $3,066.80 163
PY2025 $7,051.07 251

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $737,050.48 66
PY2024 Principal investigator $1,264,840.10 143
PY2023 Principal investigator $563,788.52 115
PY2022 Principal investigator $276,025.26 28
PY2021 Principal investigator $876,361.06 59
PY2020 Principal investigator $99,529.36 11
PY2019 Principal investigator $53,849.18 20

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

66 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,780.95 12/31/2025 Non-covered Recipient Entity
Summit Health 825 Bloomfield Avenue Obstetrics And Gynecology
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225411638
Principal investigator 1 PFIZER INC. $4,212.92 12/31/2025 Non-covered Recipient Entity
American Oncology Partners PA
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1228815499
Principal investigator 1 Janssen Research & Development, LLC $13,209.00 12/29/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) No dispute reported 06/30/2026 1175415048
Principal investigator 1 PFIZER INC. $24,273.44 12/29/2025 Covered Recipient Teaching Hospital
Amend #1 Research Medical Center
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1228708716
Principal investigator 1 PFIZER INC. $2,000.00 12/29/2025 Covered Recipient Teaching Hospital
Amend #1 Research Medical Center
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1228708720
Principal investigator 1 PFIZER INC. $28,297.52 12/29/2025 Covered Recipient Teaching Hospital
Amend #1 Research Medical Center
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1228708926
Principal investigator 1 Janssen Research & Development, LLC $1,312.00 12/25/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) No dispute reported 06/30/2026 1175415068
Principal investigator 1 Merck Sharp & Dohme LLC $21,216.00 12/22/2025 Non-covered Recipient Entity
MidAmerica Cancer Care
A Phase 1 Open-label Dose Escalation Trial of BDB018 in Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors No dispute reported 06/30/2026 1232935713
Principal investigator 1 PFIZER INC. $2,750.00 12/19/2025 Non-covered Recipient Entity
MIDAMERICA CANCER CARE
A PHASE 2B3 RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE THE EFFICACY SAFETY AND TOLERABILITY OF PONSEGROMAB PF06946860 COMPARED WITH PLACEBO BOTH WITH BACKGROUND FIRSTLINE CHEMOTHERAPY IN ADULT PARTICIPANTS WITH CACHEXIA AND METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA No dispute reported 06/30/2026 1228815134
Principal investigator 1 PFIZER INC. $18.95 12/05/2025 Non-covered Recipient Entity
MIDAMERICA CANCER CARE
A PHASE 2B3 RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE THE EFFICACY SAFETY AND TOLERABILITY OF PONSEGROMAB PF06946860 COMPARED WITH PLACEBO BOTH WITH BACKGROUND FIRSTLINE CHEMOTHERAPY IN ADULT PARTICIPANTS WITH CACHEXIA AND METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA No dispute reported 06/30/2026 1228815151
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,780.95 12/03/2025 Non-covered Recipient Entity
Summit Health 825 Bloomfield Avenue Obstetrics And Gynecology
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225411738
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,999.80 12/01/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
Fruquintinib No dispute reported 06/30/2026 1223289114
Principal investigator 1 AstraZeneca Pharmaceuticals LP $50,884.30 11/13/2025 Non-covered Recipient Entity
MIDAMERICA CANCER CARE LLC
a phase 3b,randomized,multicenter,open label study to assess the efficacy of durvalumab plus tremelimumab versus pembrolizumab in combination with platinum based chemotherapy for first line treatment in mtastatic non small cell lung cancer patients with non squamous histology who have mutations and or co mutations in skt11,keap1,or kras triton No dispute reported 06/30/2026 1185543404
Principal investigator 1 Janssen Research & Development, LLC $18,768.00 11/03/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) No dispute reported 06/30/2026 1175414992
Principal investigator 1 PFIZER INC. $1,703.70 10/24/2025 Non-covered Recipient Entity
Alliance for Multispecialty Research LLC
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1228825585
Principal investigator 1 PFIZER INC. $3,855.92 10/22/2025 Non-covered Recipient Entity
American Oncology Partners PA
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1228824964
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,780.95 10/15/2025 Non-covered Recipient Entity
Summit Health 825 Bloomfield Avenue Obstetrics And Gynecology
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225410078
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,780.95 10/15/2025 Non-covered Recipient Entity
Summit Health 825 Bloomfield Avenue Obstetrics And Gynecology
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225410086
Principal investigator 1 PFIZER INC. $4,694.24 10/15/2025 Non-covered Recipient Entity
American Oncology Partners PA
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1228825623
Principal investigator 1 Janssen Research & Development, LLC $726.00 10/02/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) No dispute reported 06/30/2026 1175415061
Principal investigator 1 Janssen Research & Development, LLC $750.00 09/29/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175415004
Principal investigator 1 Amgen Inc. $23,927.34 09/23/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA DBA ONCOLOGY HEMATOLOGY ASSOCIATES
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1246639101
Principal investigator 1 Janssen Research & Development, LLC $8,511.00 09/08/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175415042
Principal investigator 1 Amgen Inc. $5,075.00 08/23/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA DBA ONCOLOGY HEMATOLOGY ASSOCIATES
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 355 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors No dispute reported 06/30/2026 1246639099
Principal investigator 1 PFIZER INC. $14,200.00 08/23/2025 Non-covered Recipient Entity
American Oncology Partners PA
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1228830433
Principal investigator 1 Ares Trading SA $800.00 08/01/2025 Non-covered Recipient Entity
American Oncology Partners PA
A Phase II, Multicenter, Randomized, Open Label, Parallel-Arm, Umbrella Study of Avelumab (MSB0010718C) in Combination with Other Anti-Tumor Agents as a Maintenance Treatment in Participants with Locally Advanced or Metastatic Urothelial Carcinoma Whose Disease Did Not Progress with First Line Platinum-Containing Chemotherapy No dispute reported 06/30/2026 1241194005
Principal investigator 1 Ares Trading SA $1,900.00 08/01/2025 Non-covered Recipient Entity
American Oncology Partners PA
A Phase II, Multicenter, Randomized, Open Label, Parallel-Arm, Umbrella Study of Avelumab (MSB0010718C) in Combination with Other Anti-Tumor Agents as a Maintenance Treatment in Participants with Locally Advanced or Metastatic Urothelial Carcinoma Whose Disease Did Not Progress with First Line Platinum-Containing Chemotherapy No dispute reported 06/30/2026 1241194007
Principal investigator 1 Ares Trading SA $2,500.00 08/01/2025 Non-covered Recipient Entity
American Oncology Partners PA
A Phase II, Multicenter, Randomized, Open Label, Parallel-Arm, Umbrella Study of Avelumab (MSB0010718C) in Combination with Other Anti-Tumor Agents as a Maintenance Treatment in Participants with Locally Advanced or Metastatic Urothelial Carcinoma Whose Disease Did Not Progress with First Line Platinum-Containing Chemotherapy No dispute reported 06/30/2026 1241194009
Principal investigator 1 Ares Trading SA $1,100.00 08/01/2025 Non-covered Recipient Entity
American Oncology Partners PA
A Phase II, Multicenter, Randomized, Open Label, Parallel-Arm, Umbrella Study of Avelumab (MSB0010718C) in Combination with Other Anti-Tumor Agents as a Maintenance Treatment in Participants with Locally Advanced or Metastatic Urothelial Carcinoma Whose Disease Did Not Progress with First Line Platinum-Containing Chemotherapy No dispute reported 06/30/2026 1241194011
Principal investigator 1 AstraZeneca UK Limited $135,102.30 08/01/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment No dispute reported 06/30/2026 1185543400
Principal investigator 1 AstraZeneca UK Limited $173,082.65 07/30/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS P A
a phase III,open label,sponsor blind,randomized study of dato dxd with or without osimertinib versus platinum based doublet chemotherapy for participants with egfr mutated locally advanced or metastatic non small cell lung cancer whose disease has progressed on prior osimertinib treatment tropion lung15 No dispute reported 06/30/2026 1185543398
Principal investigator 1 PFIZER INC. $2,257.20 07/28/2025 Non-covered Recipient Entity
MidAmerica Cancer CareAmerican Oncology Partners
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1228713579
Principal investigator 1 Incyte Corporation $1,121.20 07/25/2025 Non-covered Recipient Entity
MIDAMERICA CANCER CARE
A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kd Inhibitor Parsaclisib Plus Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib No dispute reported 06/30/2026 1240557826
Principal investigator 1 PFIZER INC. $3,855.92 07/25/2025 Non-covered Recipient Entity
American Oncology Partners PA
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1228830195
Principal investigator 1 PFIZER INC. $6,244.04 07/16/2025 Non-covered Recipient Entity
American Oncology Partners PA
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1228830247
Principal investigator 1 Mirati Therapeutics, Inc. $22,630.00 07/15/2025 Non-covered Recipient Entity
American Oncology Partners
A Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation No dispute reported 06/30/2026 1236531279
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,780.95 07/14/2025 Non-covered Recipient Entity
Summit Health 825 Bloomfield Avenue Obstetrics And Gynecology
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225408708
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,780.95 07/14/2025 Non-covered Recipient Entity
Summit Health 825 Bloomfield Avenue Obstetrics And Gynecology
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned No dispute reported 06/30/2026 1225408730
Principal investigator 1 Janssen Research & Development, LLC $726.00 07/04/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175414984
Principal investigator 1 PFIZER INC. $3,855.92 07/02/2025 Non-covered Recipient Entity
American Oncology Partners PA
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1228830366
Principal investigator 1 PFIZER INC. $838.32 06/26/2025 Non-covered Recipient Entity
American Oncology Partners PA
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1228829431
Principal investigator 1 PFIZER INC. $3,855.92 05/30/2025 Non-covered Recipient Entity
American Oncology Partners PA
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1228829366
Principal investigator 1 PFIZER INC. $838.32 05/14/2025 Non-covered Recipient Entity
American Oncology Partners PA
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1228833488
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $13,072.00 05/02/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
Fruquintinib No dispute reported 06/30/2026 1223278892
Principal investigator 1 Janssen Research & Development, LLC $4,550.00 04/28/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175414977
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,780.95 04/24/2025 Non-covered Recipient Entity
Summit Health 825 Bloomfield Avenue Obstetrics And Gynecology
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225405616
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,780.95 04/24/2025 Non-covered Recipient Entity
Summit Health 825 Bloomfield Avenue Obstetrics And Gynecology
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225406218
Principal investigator 1 PFIZER INC. $3,855.92 04/23/2025 Non-covered Recipient Entity
Alliance for Multispecialty Research LLC
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1228832798
Principal investigator 1 PFIZER INC. $838.32 04/16/2025 Non-covered Recipient Entity
Alliance for Multispecialty Research LLC
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1228831778
Principal investigator 1 PFIZER INC. $3,855.92 04/09/2025 Non-covered Recipient Entity
Alliance for Multispecialty Research LLC
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1228833071
Principal investigator 1 Janssen Research & Development, LLC $4,838.00 04/07/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175415036
Principal investigator 1 Incyte Corporation $450.00 03/24/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors No dispute reported 06/30/2026 1240501857
Principal investigator 1 Janssen Research & Development, LLC $9,464.00 03/20/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC H LLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175400688
Principal investigator 1 PFIZER INC. $838.32 03/12/2025 Non-covered Recipient Entity
Alliance for Multispecialty Research LLC
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1228832852
Principal investigator 1 SANOFI US SERVICES INC. $480.00 03/03/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research,llc
A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226146008
Principal investigator 1 GlaxoSmithKline, LLC. $201.74 02/27/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
A PHASE 2, RANDOMIZED, PARALLEL, OPEN-LABEL STUDY TO INVESTIGATE THE S No dispute reported 06/30/2026 1192162458
Principal investigator 1 AstraZeneca Pharmaceuticals LP $10,011.40 02/13/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
a phase 3b,randomized,multicenter,open label study to assess the efficacy of durvalumab plus tremelimumab versus pembrolizumab in combination with platinum based chemotherapy for first line treatment in mtastatic non small cell lung cancer patients with non squamous histology who have mutations and or co mutations in skt11,keap1,or kras triton No dispute reported 06/30/2026 1185543402
Principal investigator 1 Janssen Research & Development, LLC $1,890.00 02/10/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC H LLC
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175400747
Principal investigator 1 Amgen Inc. $45,431.63 01/30/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1246639019
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,780.95 01/29/2025 Non-covered Recipient Entity
Summit Health 825 Bloomfield Avenue Obstetrics And Gynecology
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225403759
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,780.95 01/29/2025 Non-covered Recipient Entity
Summit Health 825 Bloomfield Avenue Obstetrics And Gynecology
BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC No dispute reported 06/30/2026 1225405732
Principal investigator 1 GlaxoSmithKline, LLC. $3,833.05 01/28/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
A PHASE 2, RANDOMIZED, PARALLEL, OPEN-LABEL STUDY TO INVESTIGATE THE S No dispute reported 06/30/2026 1192162454
Principal investigator 1 PFIZER INC. $1,600.52 01/15/2025 Non-covered Recipient Entity
Alliance for Multispecialty Research LLC
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1228832618
Principal investigator 1 ABBVIE INC. $3,206.00 01/09/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY
M18-868 - A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202437606
Principal investigator 1 PFIZER INC. $3,053.16 01/08/2025 Non-covered Recipient Entity
Alliance for Multispecialty Research LLC
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1228832020
Principal investigator 1 Amgen Inc. $12,678.08 01/02/2025 Non-covered Recipient Entity
MIDAMERICA CANCER CARE
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer No dispute reported 06/30/2026 1246644679